Month: July 2025

In recent months, Zefiro subsidiary Plants & Goodwin, Inc. (“P&G”) has continued to win awards for state-funded work in Ohio having recently announced a USD $420,784 project in Belmont County, in addition to a USD $19.6 million Construction Manager at Risk contract from the Ohio Department of Natural Resources (“ODNR”) announced on June 18, 2025. Today, Zefiro announced that P&G was recently awarded another ODNR service contract with a winning bid of USD $522,233 for remediating a group of wells in Morrow County. FORT LAUDERDALE, Fla., July 24, 2025 (GLOBE NEWSWIRE) — ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (OTCQB: ZEFIF) (the “Company”, “Zefiro”, or “ZEFI”) is pleased to announce that its subsidiary Plants & Goodwin Inc. (“P&G”) has been awarded an orphan well plugging project in Morrow...

-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for the treatment of systemic lupus erythematosus (SLE), the most common form of lupus. “Completion of enrollment in our global LUMUS Phase 2b trial for SLE marks a significant milestone for Alumis, and importantly, for the lupus community,” said Martin Babler, President and Chief Executive Officer of Alumis. “This achievement reflects the dedication of our clinical partners, investigators, patients, and the entire...

TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career scientists in biomedical research. Each year, top U.S. research universities nominate their most promising graduate students and postdoctoral fellows for this honor. These nominees are invited to develop and pitch their “dream projects” in biomedical science to a panel of Regeneron’s leading scientists, who evaluate the proposals for scientific merit, creativity and originality. This year’s winners are Alissandra L. Hillis, Ph.D., and Sreekar Mantena. Dr. Hillis is a postdoctoral fellow at the Massachusetts Institute of Technology (MIT), and...

TROY, Mich., July 24, 2025 (GLOBE NEWSWIRE) — Kelly, a leading global specialty talent solutions provider, will release its second-quarter earnings before the market opens on Thursday, August 7, 2025. In conjunction with its earnings release, Kelly will publish a financial presentation and host a live webcast of a conference call with financial analysts at 9 a.m. ET on August 7 to review the results from the quarter and answer questions. The presentation and a link to the live webcast will be accessible through the Company’s public website on the Investor Relations page under Events & Presentations. The webcast will be recorded, and a replay will be available within one hour of completion of the event through the same link as the live webcast. About Kelly Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit...

-Leadership Updates- Vancouver, BC, July 24, 2025 (GLOBE NEWSWIRE) — American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) is pleased to announce, further to its news releases of June 30, 2025 and July 17, 2025, the successful closing of its oversubscribed non-brokered private placement (the “Offering”). Pursuant to the Offering, the Company issued 14,000,000 common shares (the “Shares”) at a price of C$0.50 per Share raising gross proceeds of C$7,000,000. The strong demand from institutional investors and insiders underscores growing confidence in the Company’s vision, strategy, and momentum in the critical metals space. In consideration for providing certain finder’s services to the Company in connection with the Offering, the Company paid cash finder’s fees of an aggregate C$253,421.35...

– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy – MELBOURNE, Australia and SAN FRANCISCO, July 24, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an innovative neuroimaging measure developed in Alterity’s Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History Study was featured in the peer-reviewed journal Annals of Clinical and Translational Neurology. The publication, entitled “The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple...